A systems approach identifies HIPK2 as a key regulator of kidney fibrosis.
about
Hypoxia: The Force that Drives Chronic Kidney DiseaseRole of HIPK2 in kidney fibrosisHIPK2 is a new drug target for anti-fibrosis therapy in kidney diseaseTranscriptional corepressors HIPK1 and HIPK2 control angiogenesis via TGF-β-TAK1-dependent mechanismRTN1 mediates progression of kidney disease by inducing ER stress.Induction of retinol dehydrogenase 9 expression in podocytes attenuates kidney injury.The primary glomerulonephritides: a systems biology approach.Defining nephrotic syndrome from an integrative genomics perspective.Activation of non-canonical TGF-β1 signaling indicates an autoimmune mechanism for bone marrow fibrosis in primary myelofibrosis.Intronic locus determines SHROOM3 expression and potentiates renal allograft fibrosis.Sorafenib ameliorates renal fibrosis through inhibition of TGF-β-induced epithelial-mesenchymal transition.Fibrogenic cell reversion underlies fibrosis regression in liver.MicroRNAs in diabetic nephropathy: functions, biomarkers, and therapeutic targets.WSB1 promotes tumor metastasis by inducing pVHL degradationVascular complications of diabetes: mechanisms of injury and protective factorsMicroRNAs in HIV-associated nephropathy (HIVAN).Renoprotective effect of combined inhibition of angiotensin-converting enzyme and histone deacetylase.Rapamycin-induced modulation of miRNA expression is associated with amelioration of HIV-associated nephropathy (HIVAN).Controllability analysis of the directed human protein interaction network identifies disease genes and drug targetsAutophosphorylation and Pin1 binding coordinate DNA damage-induced HIPK2 activation and cell death.Central Nodes in Protein Interaction Networks Drive Critical Functions in Transforming Growth Factor Beta-1 Stimulated Kidney Cells.A bioinformatics approach identifies signal transducer and activator of transcription-3 and checkpoint kinase 1 as upstream regulators of kidney injury molecule-1 after kidney injury.Inhibition of the processing of miR-25 by HIPK2-Phosphorylated-MeCP2 induces NOX4 in early diabetic nephropathy.Deletion of podocyte STAT3 mitigates the entire spectrum of HIV-1-associated nephropathyHomeodomain-interacting protein kinase 2 (HIPK2): a promising target for anti-cancer therapies.Toward a systems-level understanding of the Hedgehog signaling pathway: defining the complex, robust, and fragile.The role of promoter hypermethylation in fibroblast activation and fibrogenesis.Molecular targets for treatment of kidney fibrosis.Progress in the development of animal models of acute kidney injury and its impact on drug discovery.Unilateral ureteral obstruction: beyond obstruction.How can genetics and epigenetics help the nephrologist improve the diagnosis and treatment of chronic kidney disease patients?Mechanisms of initiation and progression of intestinal fibrosis in IBD.Proteomic biomarkers in kidney disease: issues in development and implementation.Renal allograft fibrosis: biology and therapeutic targets.TSS-Seq analysis of low pH-induced gene expression in intercalated cells in the renal collecting ductBody fluid peptide and protein signatures in diabetic kidney diseases.Dissecting fibrosis: therapeutic insights from the small-molecule toolbox.A metabolite-GWAS (mGWAS) approach to unveil chronic kidney disease progression.HIPK2 modification code for cell death and survival.miR-141 regulates TGF-β1-induced epithelial-mesenchymal transition through repression of HIPK2 expression in renal tubular epithelial cells.
P2860
Q26768865-58DF7B0F-BAE9-4014-9F2A-D89FE87C058BQ26796620-B9A463D7-036B-4624-8D48-F412D02E91B8Q26996407-D1FE00B5-ECD9-425E-821F-A06C030960ABQ28585338-BF13DA99-CC3D-4E60-BB76-5B990F713AECQ30660710-A3D99827-FC75-4602-BE04-09EC561F0B52Q34103512-48F0458D-49A5-40C0-A747-562F80A6F4CCQ34462626-66D22932-378F-48AF-A700-E481120F7587Q34560989-8C6273BF-9A7F-4176-933A-9F6360F2F0DCQ35113804-4C801152-FD1E-47B6-88AC-5744978B6C16Q35242533-BF305F60-803E-4B33-80EB-DE88E7BFFE41Q35560583-725C239E-DAC0-443B-9E44-7AF3D60B7DE1Q36066433-CBEB69EE-C231-4E87-A762-DEDAD4C35EE3Q36166755-22E4AB69-CC75-4CEE-B7D1-5C7C0FAFB7C2Q36286769-818ADBF9-BD24-4651-AEE4-0E28E803735FQ36537262-7A9C9747-2B1F-4CA6-9722-13B53ED67B8BQ36581933-588446E0-A0ED-4C08-97A2-CCCAD39E42D5Q36796579-45BF6C0D-0DF8-4FCC-911B-3674B4D7BC87Q37155524-C1B229FB-7CD4-4505-9ACD-5051C3A422B0Q37173042-43C6704B-742D-4051-96FB-A4DBB7CB294AQ37318070-A6ABC5B3-FC9F-4BF3-8758-35DA69B73134Q37378227-A6D8B459-AB01-4FEC-99DC-AA656C029CAEQ37411647-1CF42E14-4232-41F1-B2A8-11B1FF624DB8Q37493523-EDEF551D-481E-4EA1-A4BA-BD34BF7B7DFDQ37571627-4B551A1E-0FC6-438F-80E4-401D832E31DBQ37746347-0B873827-5336-48A1-8B97-F96CCBD00977Q38051564-788C78E3-77AF-473D-B264-C280A20DAED9Q38055432-189DD74B-6574-4BD3-80D6-F2C6C6F4CCD1Q38062404-88391643-38F5-4483-ADA2-DD7C3D0BE79AQ38102743-7D25DAC6-BBF4-43B4-9E4C-8C0C1BF31EFDQ38144939-F6796559-B68F-4255-9B4B-617D42283CAEQ38191126-58AE3343-6097-4634-AF7B-A2D4A499CE9EQ38293779-B3EFDF55-389F-432F-BDC7-1AF0DD3AB4B6Q38341211-A03BD9F7-1F3C-4E55-917B-D5E7202454AFQ38359455-EA485DB7-D0FD-45E8-8D1D-1FF693B67BAEQ38429142-E0A970E5-E0BC-4485-89C6-484BE3071EADQ38553924-C37EC036-02AB-490C-8F7C-64F1EE57460DQ38580461-1FE80AA0-4254-4331-9262-6299254E90B7Q38787907-2E275509-1B4B-4F8D-BB9B-8A4E20188A58Q38866672-C359539A-8D92-4990-A1D5-4E60028D76D2Q38938083-08C53073-5CF4-4BE7-9077-853E5A5BC61B
P2860
A systems approach identifies HIPK2 as a key regulator of kidney fibrosis.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
A systems approach identifies HIPK2 as a key regulator of kidney fibrosis.
@en
A systems approach identifies HIPK2 as a key regulator of kidney fibrosis.
@nl
type
label
A systems approach identifies HIPK2 as a key regulator of kidney fibrosis.
@en
A systems approach identifies HIPK2 as a key regulator of kidney fibrosis.
@nl
prefLabel
A systems approach identifies HIPK2 as a key regulator of kidney fibrosis.
@en
A systems approach identifies HIPK2 as a key regulator of kidney fibrosis.
@nl
P2093
P2860
P356
P1433
P1476
A systems approach identifies HIPK2 as a key regulator of kidney fibrosis.
@en
P2093
Amin R Mazloom
Edward Y Chen
Huabao Xiong
John Cijiang He
Krishna Ratnam
Michael J Ross
Peter Y Chuang
Vivette D'Agati
P2860
P2888
P304
P356
10.1038/NM.2685
P407
P50
P577
2012-03-11T00:00:00Z